2Wechalekar AD,Gillmore JD,Bird J,et al.Guidelines on the management of AL amyloidosis[J].Br J Haematol,2015,168:186-206.
3Palladini G,Hegenbart U,Milani P,et al.A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis[J].Blood,2014,124:2325-2332.
4Wechalekar AD,Schonland SO,Kastritis E,et al.A European collaborative study of treatment outcomes in346 patients with cardiac stage III AL amyloidosis[J].Blood,2013,121:3420-3427.
5Bochtler T,Hegenbart U,Kunz C,et al.Gain of chromosome 1q21is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexame-thasone[J].Amyloid,2014,21:9-17.
6Bochtler T,Hegenbart U,Kunz C,et al.Translocation t(11;14)is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens[J].J Clin Oncol,2015,33:1371-1378.
7Warsame R,Kumar SK,Gertz MA,et al.Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death[J].Blood Cancer,2015,5:e310.
8Palladini G,Dispenzieri A,Gertz MA,et al.New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers:impact on survival outcomes[J].J Clin Oncol,2012,30:4541-4549.
9Fernandez de Larrea C,Verga L,Morbini P,et al.A practical approach to the diagnosis of systemic amyloidoses[J].Blood,2015,125:2239-2244.
10Kristen AV,aus dem Siepen F,Scherer K,et al.Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging[J].Amyloid,2015,22:132-141.
